Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions
Primary Purpose
Skin Lesion
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dermal Cooling System
Sponsored by
About this trial
This is an interventional treatment trial for Skin Lesion
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects > 18 years of age.
- Subject has a skin condition amenable to cryosurgical treatment including, for example, psoriasis, atopic dermatitis, acne, rosacea, and melasma.
- Subject is willing to have skin exposed to cooling with the Dermal Cooling System.
- Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
- Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested.
- Subject has read and signed a written informed consent form.
- Subject is willing to comply with adjuvant topical regimen, as applicable.
- Subject agrees not to undergo any other procedure(s) in the treatment area during the study.
Exclusion Criteria:
- Dermatological conditions (e.g. vitiligo, open wounds, infection, pre-cancerous or malignant lesions) in the location of the treatment sites that would, in the professional opinion of the investigator, potentially pose an increased risk to the subject
- Use of Accutane within the previous 6 months
- History of melanoma
- Subject is pregnant or intending to become pregnant during the study period
- Subject is lactating or has been lactating in the past 6 months
- Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
- History of abnormal wound healing or abnormal scarring
- Inability or unwillingness to comply with the study requirements.
- Current enrollment in a clinical study of any other unapproved investigational drug or device.
- Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Sites / Locations
- West Coast ResearchRecruiting
- Oak DermatologyRecruiting
- Skin Search of Rochester, Inc.Recruiting
- Dermatology, Laser and Vein Specialists of the CarolinasRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment with Dermal Cooling System
Arm Description
Dermal Cooling System will be used in all eligible subjects.
Outcomes
Primary Outcome Measures
Change in appearance in the treated area as determined by the Physician Global Assessment (PGA).
Investigator assessment using Physician Global Assessment (PGA); graded from "4" (very much improved") to "0" (worse).
Incidence of treatment-emergent adverse events
The safety of the treatment is determined by the incidence of device- or procedure-related serious adverse events.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05270512
Brief Title
Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions
Official Title
Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 10, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
R2 Dermatology
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate whether the Dermal Cooling System can be used to elicit an improvement in the cosmetic appearance or physical symptoms of common skin conditions.
Detailed Description
This is a prospective, non-randomized, open-label study to evaluate the effectiveness of the Dermal Cooling system to determine if cosmetic benefits or physical symptoms are achieved in common skin conditions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Lesion
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Treatment with Dermal Cooling System
Arm Type
Experimental
Arm Description
Dermal Cooling System will be used in all eligible subjects.
Intervention Type
Device
Intervention Name(s)
Dermal Cooling System
Intervention Description
Controlled localized cooling may be applied to lesions using the Dermal Cooling System.
Primary Outcome Measure Information:
Title
Change in appearance in the treated area as determined by the Physician Global Assessment (PGA).
Description
Investigator assessment using Physician Global Assessment (PGA); graded from "4" (very much improved") to "0" (worse).
Time Frame
up to 3 months
Title
Incidence of treatment-emergent adverse events
Description
The safety of the treatment is determined by the incidence of device- or procedure-related serious adverse events.
Time Frame
Up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female subjects > 18 years of age.
Subject has a skin condition amenable to cryosurgical treatment including, for example, psoriasis, atopic dermatitis, acne, rosacea, and melasma.
Subject is willing to have skin exposed to cooling with the Dermal Cooling System.
Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area for the duration of the study, including the follow-up period, if requested.
Subject has read and signed a written informed consent form.
Subject is willing to comply with adjuvant topical regimen, as applicable.
Subject agrees not to undergo any other procedure(s) in the treatment area during the study.
Exclusion Criteria:
Dermatological conditions (e.g. vitiligo, open wounds, infection, pre-cancerous or malignant lesions) in the location of the treatment sites that would, in the professional opinion of the investigator, potentially pose an increased risk to the subject
Use of Accutane within the previous 6 months
History of melanoma
Subject is pregnant or intending to become pregnant during the study period
Subject is lactating or has been lactating in the past 6 months
Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
History of abnormal wound healing or abnormal scarring
Inability or unwillingness to comply with the study requirements.
Current enrollment in a clinical study of any other unapproved investigational drug or device.
Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dennell A Vargas
Phone
5104152038
Email
dvargas@r2technologies.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristine Tatsutani, PhD
Organizational Affiliation
R2 Technologies
Official's Role
Study Director
Facility Information:
Facility Name
West Coast Research
City
Dublin
State/Province
California
ZIP/Postal Code
94568
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tim Davis
Phone
925-413-1451
Email
tdavis@westcoastresearch.com
First Name & Middle Initial & Last Name & Degree
Alfred E Tan, MD
Facility Name
Oak Dermatology
City
Naperville
State/Province
Illinois
ZIP/Postal Code
60563
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peri Todd, MS
Phone
630-931-0886
Email
peri.todd@oakderm.com
First Name & Middle Initial & Last Name & Degree
Ashish C Bhatia, MD
Facility Name
Skin Search of Rochester, Inc.
City
Rochester
State/Province
New York
ZIP/Postal Code
14623
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Denise Forster, BS
Phone
585-697-1818
Email
dforster@dermrochester.com
First Name & Middle Initial & Last Name & Degree
Leslie Loss, MD
Facility Name
Dermatology, Laser and Vein Specialists of the Carolinas
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Razia Ludin, BSc
Phone
704-973-3687
Email
RaziaL@carolinaskin.com
First Name & Middle Initial & Last Name & Degree
Girish Munavalli, MD
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions
We'll reach out to this number within 24 hrs